An interventional study of computed tomography perfusion guided treatment and Fractional flow reserve guided treatment in Coronary Disease, sponsored by Young-Hak Kim, MD, PhD. Recruiting at 7 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-04-05.
Sponsored by Young-Hak Kim, MD, PhD · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Coronary Disease with a site in Korea, Republic of — 6 open to participants now, 7 under way, none of them phase 3. Coronary Disease · Korea, Republic of.
Among the 49 studies in Coronary Disease with a site in Korea, Republic of, this one is the 15th largest by planned enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2014, is one of 7 with no phase, and was the 28th registered.
1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →6 of the 49 studies in Coronary Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Seung-Whan Lee, M.D., Ph.D. · Sites in Korea, Republic of
Ages 19+
Jung-min Ahn · Sites in Korea, Republic of
Ages 19+
Seung-Jung Park · Sites in Korea, Republic of
Ages 19+
Jung-min Ahn · Sites in Korea, Republic of
Ages 20+
Seung-Jung Park · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 160 across 780 interventional studies indexed under Coronary Disease.
Median enrollment 1,000 across the 29 interventional studies, 1,125 across the 20 observational. Of the 34 that completed or were terminated, 7 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 49 have an industry lead sponsor. The 10 most frequent:
Young-Hak Kim, MD, PhD is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Young-Hak Kim, MD, PhD has 1 study filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Coronary Disease with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05044273Jung-min AhnEvaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent | 2026-12-31 |
| NCT05529459Seung-Whan Lee, M.D., Ph.D.Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 49 studies in Coronary Disease with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate safety and effectiveness of CTP(computed tomography perfusion) guided revascularization vs FFR(Fractional flow reserve) guided revascularization
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with Computed tomography perfusion
Device: computed tomography perfusion guided treatment
Patients with Fractional flow reserve
Device: Fractional flow reserve guided treatment
Composite Events
All cause death, Myocardial infarction, Diseased-related unplanned hospitalization or stroke
Time frame: 1 year
All cause death
All cause death
Time frame: 5 year
Myocardial infarction
Myocardial infarction
Time frame: 5 year
Target vessel revascularization
Target vessel revascularization
Time frame: 5 year
Stent thrombosis
Stent thrombosis
Time frame: 5 year
Seattle Angina Questionnaire,EQ5D questionnaire
Quality of life score assessed by the EQ-5D-5L The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Higher score of EQ-5D and EQ VAS means the low quality of life. EQ-5D: the minimum and maximum values are 5 and 25 respectively. EQ VAS: the minimum and maximum values are 0 and 100 respectively. Seattle Angina Questionnaire The Seattle Angina Questionnaire (SAQ) is a vali- dated disease-specific instrument for assessing the health status of patients with coronary artery disease. SAQ scores can be aligned with clinical constructs (eg, scores on the SAQ angina frequency scale of 0-30 points indicate daily angina, 31-60 points indicate weekly angina, 61-99 points indicate monthly angina, and 100 points indicate no angina)
Time frame: 5 year
Success of intervention
Defined as mean lesion diameter stenosis ≤50% and without the occurrence of in-hospital myocardial infarction (MI), target vessel revascularization (TVR), or death
Time frame: 5 year
Cost effective analysis
Cost effective analysis
Time frame: 1 year
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Started Aug 2014 (actual). Primary completion is estimated for Mar 2028, 162 months after the start.
Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 162 months is above that.
Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Young-Hak Kim, MD, PhD